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From the Trudeau Institute, Inc. Saranac Lake, New York 12983
Evidence was presented in the preceding paper (1) to support the interpretation that,
although parenteral administration of bacterialendotoxin causes hemorrhagic necrosis of most
established, syngeneic murine tumors, it is only those tumors that are immunogenic enough to
evoke the generation of T-cell-mediated immunity that subsequently go on to completely
regress. It was suggested, therefore, that tumor regression, but not hemorrhagic necrosis, is
mediated by an acquired population of specifically sensitized T cells.
However, a recent series of published papers (2-5) has implicated a host molecule(s), called
tumor necrosis factor, in the mediation of the anti-tumor effects of endotoxin. The evidence in
these same papers strongly suggests, moreover, that an activated macrophage system is an
essential requirement for the endotoxin-induced liberation of this molecule, in that it is only
released into the circulation of mice that have had their macrophage systems activated by
Bacillus Calmette-Guerin (BCG),t Corynebacterium parvum, or other agents known to activate
macrophages. It is apparent, however, that it has yet to be shown that tumornecrosis factor is
liberated in tumor-bearing mice themselves. This would seem important to know, because if,
indeed, tumor necrosis factor is the mediator of the anti-tumor effects of endotoxin, then it
would follow that those tumors that regress in response to endotoxin therapy must be capable
by themselves of priming the host to liberate tumor necrosis factor by virtue of theircapacity
for evoking the generation of an activated macrophage system. In support ofthis possibility, a
recent publication from this laboratory shows (6) that subcutaneous growth of the SA-1
sarcoma, a tumor that predictably regresses completely in response to endotoxin therapy (1),
causes the generation of a highly activated macrophage system, as evidenced by a greatly
increased macrophage-mediated capacity for resisting experimental infection with bacterial
parasites. It is possible, therefore, that an activated macrophage system is generated in response
to growth of all endotoxin-susceptible tumors.
In addition, it is difficult to reconcile the evidence for a direct role for tumor
necrosis factor in the mediation of endotoxin-induced tumor regression, with that
which strongly suggests that tumor regression is dependent on the acquisition of T-
cell-mediated immunity (1). Presumably, if tumor necrosis factor does play a role in
tumor regression, it does so either by augmenting the generation of T-cell-mediated
immunity by virtue of its reported immunoregulatory properties (5), or alternatively,
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by creating conditions within the tumor, via hemorrhagic necrosis, that are conducive
to the entry and functioning of effector T cells. The alternative explanation would
require, however, that a potential immune effector mechanism must already exist
before endotoxin is administered. The purpose of this paper is to show that such an
effector mechanism already exists in the form of concomitant anti-tumor immunity.
It will also show that it is only those tumors that evoke this form of anti-tumor
immunity which are susceptible to endotoxin-induced regression.
Materials and Methods
The materials and methods employed were the same as those described in the preceding
companion paper (1), except for additional procedures that were used to measure macrophage-
mediated anti-bacterial resistance and concomitant anti-tumor immunity in tumor-bearing
mice.
Anti-Bacterial Resistance.
￿
Changes against time in the level of macrophage-mediated, non-
specific, anti-bacterial resistance in response to tumor growth were measured in terms of
changes in the capacity of the host to resist a standard 105 intravenous challenge with the
intracellular, bacterial parasite, L. monocytogenes (strain EGD) . Anti-bacterial resistance was
recorded as changes in loglo resistance which were obtained by subtracting the 48-h growth of
the organism in the livers of tumor bearers from its 48 h growth in the livers ofcontrols. A log
phase culture of L. monocytogenes seeded from an infected mouse spleen, was grown in trypticase-
soy broth, and stored in small aliquots at -70°C. Before each experiment an aliquot was
quickly thawed and diluted in 0.9% sodium chloride solution for intravenous inoculation as
described previously (7). Bacteria were enumerated by plating 10-fold serial dilutions ofwhole
liver homogenates on trypticase-soy agar.
Concomitant Immunity.
￿
Concomitant immunity generated in response to growth of intrader-
mal tumors was measured as the ability of the host to suppress the growth of 106 cells of the
same tumors implanted in the right-hind footpad. Tumor growth was monitored by measuring
increases in the dorsoventral thickness of the footpad with dial calipers as described before (6).
Results
Evidence That the Acquisition ofConcomitant Immunity Precedes Endotoxin Susceptibility.
￿
A
review of the literature (8) indicates that tumors must be above a certain critical size
before they become susceptible to the anti-tumor effects of endotoxin. It is apparent,
moreover, that with certain transplantable tumors, such as the Meth A fibrosarcoma
(2), the period of endotoxin susceptibility is relatively brief, a characteristic that is
undoubtedly responsible for the unpredictable results obtained with this tumor.
Although there are a number of possible reasons for these findings, it is tempting, in
view of the results presented in the preceding companion paper (1), to give them an
immunological explanation. It is already known from published experiments (6), for
instance, that the highly endotoxin-susceptible SA-1 sarcoma, after a certain stage of
growth, evokes the generation of T-cell-mediated concomitant immunity. On the
other hand, the results of unpublished pilot experiments show that concomitant
immunity is not generated in response to growth of the endotoxin-resistant BP3
sarcoma. This information, plus the knowledge that endotoxin-induced regression is
dependent on T-cell-mediated immunity (1), suggests the possibility that endotoxin-
induced regression depends on the acquisition by the host of a state of concomitant
anti-tumor immunity.
Testing this suggestion involved making concurrent measurements against time of
tumor growth of changes in (a) susceptibility to endotoxin-induced regression, (b)
concomitant resistance to growth of a standard subcutaneous tumor implant, and (c)1562 IMMUNOLOGICAL BASIS OF ENDOTOXIN-INDUCED TUMOR REGRESSION. II
FIG. 1 . Changes against time of intradermal SA-1 growth in : (a) susceptibility to endotoxin-
induced regression (top graphs), (b) the level of concomitant immunity to growth of a standard 10 6
tumor cell challenge implanted subcutaneously in the right-hind footpad (bottom graphs), and (c)
logio protection expressed in the liver against a standard 105 intravenous challenge with L .
monocytogenes (histobars) . The larger numerals on the abscissa represent days ofgrowth oftheprimary
tumor .Thesmallnumbers refer to days ofmeasurement ofthe in vivo assays . It can be seen that the
SA-1 sarcoma was susceptible to endotoxin-induced regression at all times tested after day 3 of
growth, even when the tumors had reached a very large size . Concomitant immunity was not
immediately expressed against a challenge implant until 6 days growth of the primary tumor, and
was sustained at ahigh level until theend of theexperiment. Likewise, macrophage-mediated anti-
bacterial resistance was not acquired until day 6of tumor growth,andwas sustained at ahigh level
thereafter.
The- results indicate that the SA-1 sarcoma did not become susceptible to endotoxin-induced
regression untilday 6when concomitant immunity and macrophage activation reached high levels .
Means of five mice per time interval .
systemic macrophage activation, as evidenced by changes in the level of macrophage-
mediated anti-bacterial resistance . Making these concurrent measurements required
the use of over 300 mice for each of the four tumors studied . The tumors studied were
the same as in the preceding paper, and were the endotoxin-susceptible SA-1 and
Meth A fibrosarcomas, and the endotoxin-resistant BP3 sarcoma andCaD2 mammary
carcinoma . The results in Figs . 1-4 are consistent with the hypothesis that endotoxin-
induced regression requires the preceding generation of a state of concomitant anti-
tumor immunity .
The SA-1 Sarcoma.
￿
It can be seen in Fig. 1 that a single intravenous injection of
endotoxin given at any time after day 3 of SA-1 implantation resulted, in all cases, in
hemorrhagic necrosis and substantial tumor regression . With 6 dayand 9 day tumors,
regression was complete, and was not followed by tumor regrowth in the 10 additional
animals that were kept for visual inspection over a 60 day period . However, with the
very large 12 and 15 day tumors, regression, although very substantial, was not
complete in all animals . Of the additional animals kept for visual inspection, 4 out ofM . J . BERENDT, R . J . NORTH, AND D. P. KIRSTEIN
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Ftc . 2. Same as for Fig. l, but with the Meth A fibrosarcoma . This tumor only completely
regressed in response to an injection ofendotoxin given on day 6 . It was also only on day6 that a
significant level of concomitant immunity was expressed against a tumor challenge implant, and
that macrophage-mediated anti-bacterial resistance reached its highest level. Means of five mice per
time interval.
10 ofthe 12 daytumors,and 6out of 10 ofthe 15 day tumors soon regrew progressively
from very thin rings of surviving tumor tissue .
As expected from a previous study {6}, intradermal growth of the SA-1 sarcoma
evoked the generation of a high and sustained level of concomitant anti-tumor
immunity . It wasnot immediatelyexpressedagainsta 106challengeimplant, however,
until after 6 days of growth of the primary tumor. It will be noted in this connection
that although growth of the 3 day challenge implant was significantly suppressed, it
was not suppressed until after a 3-day delay. Presumably, therefore, rapid generation
of concomitant immunity occurred between days 6 and 9.
Likewise, increased macrophage-mediated anti-bacterial resistance to an intrave-
nous Listeria challenge apparently was generated between days 6 and 9 of tumor
growth, and was sustained at a high level until the experiment was terminated . It can
be seen that from day 6 o£ tumor growth on, the standard Listeria challenge grew
about 21ogs less in the livers oftumor bearersthan in the livers ofcontrol mice during
a 48-h period . It should be realized that, since anti-bacterial resistance was measured
48 h after thechallenge times show in Fig. 1, the 2 logs protection apparently present
on day 6may not have been fully acquired at this time .
Taken together, the results with the SA-1 sarcoma show that this tumor was
exquisitely sensitive to endotoxin-induced regression, but only after the host had
begun to generate concomitant immunity and an activated macrophage system .
The MethA Fibrosarcoma.
￿
Theresultswith theMethAfibrosarcoma are p
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Fic . 3 .
￿
Same as for Fig . 1, but with the CaD2 mammary carcinoma . This tumor was resistant to
endotoxin-induced regression at all stages ofgrowth . In addition, only a very low level of concomitant
immunity was generated, although macrophage-mediated anti-bacterial resistance reached appre-
ciable levels by day 2 . Means of five mice per time interval .
induced regression for only a brief period of its growth . Only 6 day tumors completely
regressed in response to intravenous administration of endotoxin . It was the combi-
nation of hemorrhagic necrosis and partial regression that was responsible for the
initial drop in weight of older tumors shown in Fig. 2 .
Concomitant immunity to a subcutaneous Meth A challenge implant was expressed
at a significant level only on days 3 and 6 of growth ofthe primary tumor . The results
indicate however, that there was a delay before growth of the 3 day challenge was
suppressed . This means that peakimmunity was not acquired until some time between
days 6 and 9. Therefore, unlike concomitant immunity to the SA-1, concomitant
immunity to the Meth A was not sustained at a level that was high enough to
completely prevent growth of the standard challenge implant .
As with concomitant immunity, the highest level of macrophage-mediated anti-
bacterial resistance was expressed against a bacterial challenge given on day 6 of
tumor growth . Anti-bacterial resistance declined significantly by day 9, and remained
at this reduced level until the experiment was terminated . Taken together, therefore,
the results in Fig . 2 strongly suggest that the Meth A fibrosarcoma was susceptible to
complete regression by endotoxin only during a relatively brief period when concom-
itant immunity and macrophage activation were at their highest levels .
The CaD2 Mammary Carcinoma andBP3 Sarcoma .
￿
The results with these two tumors
are described together, because they were both shown to be poorly immunogenic, and
to be resistant to endotoxin-induced regression when tested at 7 days of growth (1) .
Indeed, it can be seen in Figs . 3 and 4 that both tumors failed to regress appreciably
in response to an intravenous injection ofendotoxin given at any stage during 15 days
of growth . The apparent temporary cessation of growth which occurred in all casesM. J . BERENDT, R. J. NORTH, AND D . P . KIRSTEIN
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FIG . 4 .
￿
Same as for Fig . 1, but with the BP3 fibrosarcoma . Like theCaD2 tumor, this tumor was
not susceptible to endotoxin-induced regression at any stage of its growth . Concomitant immunity
to achallenge implant was not acquired, and increased anti-bacterial resistance was not generated
at a significant level until the tumor became very large . Means of five mice per time interval .
after endotoxin administration, was caused by loss of the cores of the tumors because
of central hemorrhagic necrosis, which was more extensive with increasing size of the
tumors .
Concomitant resistance to growth of a standard subcutaneous challenge implant
was not detected at any given time in mice bearing the BP3 sarcoma, and only low
levels of resistance were measured in CaD2 bearers . However, the behavior of the
CaD2 challenge implant was peculiar, in that it first grew substantially as in controls
before showing a slower rate of growth .
Increased macrophage-mediated anti-bacterial resistance was generated in response
to growth of each tumor, but did not reach appreciable levels until later stages of
tumor growth . The results with these two tumors indicate, therefore, that lack of
susceptibility to endotoxin-induced regression was associated with the absence of
significant levels of concomitant anti-tumor immunity, rather than with the absence
of an activated macrophage system.
Reduced Level of Concomitant Immunity in T-Cell-Deficient Mice.
￿
It was shown in the
preceding companion paper (1) that endotoxin injection failed to cause the regression
of susceptible SA-1 and Meth A tumors growing in T-cell-deficient mice . It was
established (6) in a previous publication, moreover, that T-cell-deficient mice bearing
the SA-1 sarcoma also failed to generate concomitant immunity . It was the purpose
of the following experiments, therefore, to determine whether T-cell deficiency also
results in a failure of syngeneic mice to generate concomitant immunity in response
to growth of the Meth A fibrosarcoma . If so, then it would represent additional
evidence consistent with the hypothesis that the generation ofconcomitant immunity
is a prerequisite for endotoxin-induced regression .1566 IMMUNOLOGICAL BASIS OF ENDOTOXIN-INDUCED TUMOR REGRESSION. II
70-
60-
-- 50- E
E
° 40-
0 f
30-
%B
TUMOR
BEARER
. .. ... TUMOR BEARER
3 6 9 12 15 18
DAYS AFTER CHALLENGE
Ftc. 5.
￿
Evidence that concomitant immunity to the Meth A sarcoma was not generated by mice
that were made T-cell-deficient by thymectomy and gamma-irradiation (THXB), and restored with
bone marrow. Growth of 106 Meth A cell challenge implant was completely suppressed by mice
bearing 6 day intradermal primary tumors, but was only slightly suppressed by THXB mice bearing
6 day tumors. Tumor-bearing, irradiated, bone marrow protected controls (XB) behaved like
normal tumor-bearing mice.
The results in Fig. 5 support the hypothesis. They show that whereas 6 days of
intradermal growth of the Meth A sarcoma resulted in a high enough level of
concomitant immunity to completely suppress the growth of a 106 Meth A challenge
implant, growth of the same challenge implant was only slightly suppressed in 6 day
tumor-bearing mice that had been made T-cell deficient by thymectomy and gamma-
irradiation.
The Specificity of Endotoxin-Induced Regression.
￿
In the absence of direct evidence that
sensitized T cells are the actual effectors of endotoxin-induced regression, and in view
of the foregoing evidence that mice bearing endotoxin-susceptible tumors possess a
possible nonspecific anti-tumor mechanism in the form of an activated macrophage
system, it might still be argued that macrophages, and not sensitized T cells are the
effectors of tumor regression. According to this explanation, the major purpose of
sensitized T cells would be to mediate an adequate level of macrophage activation. If
this were the case, however, then it might be expected that endotoxin, perhaps
through events initiated by the action of tumor necrosis factor, would nonspecifically
regress any nonimmunogenic tumor provided the host had acquired an activated
macrophage system.
That this is almost certainly not the case is shown in Fig. 6 where it can be seen
that simultaneous intradermal growth of the endotoxin-susceptible SA-1 sarcoma and
the endotoxin-resistant BP3 sarcoma on the same semisyngeneic AB6Ft host did not
create conditions that enabled endotoxin to regress the BP3 sarcoma. Thus, when
endotoxin was injected intravenously into these double tumor bearers, only the SA-1
tumor underwent regression. In other words, each tumor behaved as if it were growing
alone on its own host. The highly activated macrophage system generated in responseM. J. BERENDT, R. J. NORTH, AND D. P. KIRSTEIN
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FiG. 6. The specificity of endotoxin-induced tumor regression is illustrated by the effect of
endotoxin injection (arrows) on the endotoxin-susceptible SA-1 sarcoma and the endotoxin-resistant
BP3 sarcoma both growing simultaneously on the same mouse. Only the SA-1 regressed, and each
tumor behaved as though it were growing alone on its own host. Means of five mice per time
interval.
to the SA-1 sarcoma, therefore, did not impart on the host the capacity to regress the
BP3 tumor.
Discussion
The results-of this paper and the preceding paper (1) are consistent with the
hypothesis that endotoxin-induced regression ofestablished, syngeneic, murine tumors
depends on the preceding generation of a state of concomitant anti-tumor immunity
which in the case of the SA-1 sarcoma is known to be T-cell-mediated (6). Of the four
tumors investigated, only those two that were shown to be immunogenic as classically
defined (1), and which could evoke a paradoxical state of concomitant anti-tumor
immunity, regressed in response to endotoxin therapy. The results show, in addition,
that a brief period of concomitant immunity generated in response to the Meth A
sarcoma results in a correspondingly brief period of susceptibility to endotoxin-
induced regression, hence, the reason for the unpredictable results obtained with this
tumor. Hemorrhagic necrosis, on the other hand, occurred at all stages of growth of
immunogenic as well as nonimmunogenic tumors, and was responsible for the
apparent temporary cessation of tumor growth and temporary reduction in weight of
nonsusceptible tumors.
These results point to the conclusion that endotoxin-induced regression is accom-
plished by the tumoricidal action of specifically-sensitized T cells, rather than by the
action of a soluble molecular mediator, such as tumor necrosis factor (2) . The finding
that an injection of endotoxin given to mice bearing both an endotoxin-susceptible
and an endotoxin-resistant tumor, resulted in regression of only the susceptible tumor
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argues against the participation of a circulating factor that is selectively cytotoxic for
neoplastic cells in general (5) . It is possible, nevertheless, that such a factor is
responsible for the mediation of hemorrhagic necrosis which was shown here to occur
in the absence ofT-cell-mediated anti-tumor immunity. Indeed, it seems highly likely
that the destructive effects caused by hemorrhagic necrosis in the nutrient-starved
core of the tumor are necessary for creating conditions that are conducive to the entry
of an already acquired population of specifically-sensitized effector T cells. This could
be achieved by the creation of a local inflammatory response inside the tumor, or by
the elimination ofa local immunosuppressor mechanism, or both. The possibility that
hemorrhagic necrosis serves to augment T-cell-mediated immunity by causing the
release of increased quantities of tumor specific antigens should also be considered.
In any case, the demonstration of an immunological basis of endotoxin-induced
tumor regression means that endotoxin should be properly viewed as an immuno-
therapeutic agent, possibly with a different mode of action than other immunother-
apeutic agents, such as BCG and Corynebacterium parvum. The results with endotoxin
indicate the need, moreover, for giving much more attention to the properties that
tumors might need to possess for immunotherapeutic agents to give an anti-tumor
effect. It is perhaps surprising in this regard that most published studies of tumor
immunotherapy do not even take into account the antigenicity or immunogenicity of
the tumors under investigation. The present study indicates that, so far as endotoxin
therapy is concerned, tumor immunogenicity is perhaps the most important property
to be considered. It should be brought to mind that a successful immunotherapeutic
response should not only be evidenced by regression of the primary tumor, but also
by the generation of a state of immunologic memory with the potential to suppress
the growth of disseminated tumor cells that can later emerge as secondary tumors. It
is apparent, however, that additional factors operate to determine the success of an
immunotherapeutic modality. For example, the capacity of the tumor, under the
pressure of host defenses, to generate cells that are resistant to native and acquired
mechanisms ofantitumor resistance is a distinct possibility (9-11) . It is already known
from this study, for instance, that endotoxin immunotherapy suffers from the same
limitations as other forms of immunotherapy, in that endotoxin-induced complete
regression ofa primary SA-1 sarcoma is no guarantee that already seeded lymph node
metastases will not eventually grow to kill the host.
Apart from a possible role in the liberation of tumor necrosis factor, the significance
of the acquisition of a highly activated macrophage system to the antitumor effects of
endotoxin is not known. According to purely in vitro evidence (12), it would provide
an additional antitumor effector mechanism. It seems fairly clear, from this study,
however, that the presence of these cells systemically is of little use, in the absence of
an immune effector mechanism, in causing the regression ofsolid tumors. It is possible,
nevertheless, that activated macrophages may be present in large enough numbers
locally, or can be drawn from circulation to aid in the immunological destruction of
immunogenic tumors. It should also be realized that macrophages undoubtedly play
a major role in the resorption of dead tumor tissue which is measured as regression.
It can be pointed out in conclusion, that the present studies, like most published
studies of immunotherapy, do not provide direct evidence that sensitized T-cells are
the actual efectors of tumor regression in vivo. This would require the demonstration
in endotoxin-treated, T-cell-deficient recipient mice, of tumor regression after intra-venous infusion of specifically sensitized T cells from immune donors. This demon-
stration will appear in a forthcoming publication.
Summary
It was shown that of four syngeneic, murine tumors investigated, only those that
evoked the generation ofa state of concomitant anti-tumor immunity were susceptible
to endotoxin-induced regression. Moreover, the temporal relationship between the
generation of concomitant immunity and the onset of susceptibility to endotoxin-
induced regression points to the likely possibility that tumor regression depends on
the preceding acquisition of the specifically-sensitized, effector T cells that express
concomitant immunity. It is suggested that endotoxin-induced hemorrhagic necrosis
which invariably precedes tumor regression serves to create conditions inside the
tumor that are conducive to the entry and the functioning of effector T cells. It is also
suggested that tumor necrosis factor causes hemorrhagic necrosis rather than tumor
regression.
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